pr400124w_si_002.pdf (84.45 kB)
Functional Classification of Cellular Proteome Profiles Support the Identification of Drug Resistance Signatures in Melanoma Cells
journal contributionposted on 2015-12-16, 23:07 authored by Verena Paulitschke, Verena Haudek-Prinz, Johannes Griss, Walter Berger, Thomas Mohr, Hubert Pehamberger, Rainer Kunstfeld, Christopher Gerner
Drug resistance is a major obstacle in melanoma treatment. Recognition of specific resistance patterns, the understanding of the patho-physiology of drug resistance, and identification of remaining options for individual melanoma treatment would greatly improve therapeutic success. We performed mass spectrometry-based proteome profiling of A375 melanoma cells and HeLa cells characterized as sensitive to cisplatin in comparison to cisplatin resistant M24met and TMFI melanoma cells. Cells were fractionated into cytoplasm, nuclei and secretome and the proteome profiles classified according to Gene Ontology. The cisplatin resistant cells displayed increased expression of lysosomal as well as Ca2+ ion binding and cell adherence proteins. These findings were confirmed using Lysotracker Red staining and cell adhesion assays with a panel of extracellular matrix proteins. To discriminate specific survival proteins, we selected constitutively expressed proteins of resistant M24met cells which were found expressed upon challenging the sensitive A375 cells. Using the CPL/MUW proteome database, the selected lysosomal, cell adherence and survival proteins apparently specifying resistant cells were narrowed down to 47 proteins representing a potential resistance signature. These were tested against our proteomics database comprising more than 200 different cell types/cell states for its predictive power. We provide evidence that this signature enables the automated assignment of resistance features as readout from proteome profiles of any human cell type. Proteome profiling and bioinformatic processing may thus support the understanding of drug resistance mechanism, eventually guiding patient tailored therapy.
survival proteins375 melanoma cellsMelanoma CellsDrug resistanceTMFI melanoma cellscell adhesion assaysCPLdrug resistance mechanismproteome profilesextracellular matrix proteinsM 24met cellscell adherence proteinsLysotracker Red stainingmelanoma treatmentCellular Proteome Profiles SupportDrug Resistance Signatures